^
Association details:
Biomarker:EGFR L861Q
Cancer:Lung Adenocarcinoma
Drug:Conmana (icotinib) (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors

Published date:
06/06/2022
Excerpt:
In this study, two EGFR L861Q variants cell lines (EGFR L861Q variant and EGFR L861Q + exon 19 deletion variant) were established by CRISPR-Cas9 gene-editing technology. The steady-state plasma concentrations of six TKIs (gefitinib/erlotinib/icotinib, the first generation; dacomitinib/afatinib, the second generation; and osimertinib, the third generation) were tested, respectively....EGFR L861Q + 19del variant and EGFR L861Q variant showed significant sensitivity to six first-in-class TKIs.
DOI:
https://doi.org/10.1007/s12094-022-02854-3